Cryptocurrencies
Nordic Nanovector Provides Update On PARADIGME, Its Phase 2b Pivotal Trial With Betalutin® In R/R Follicular Lymphoma
OSLO, Norway, Jan. 7, 2022 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin ® ( 177Lu lilotomab satetraxetan) in 3 Read more…